Annals of surgical oncology · 2026
Oncologic Safety of Preoperative Controlled Ovarian Stimulation for Fertility Preservation Among Women with Estrogen Receptor Positive Breast Cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Jennifer H, Peregrin-Alvarez Irene, Warneke Carla L, McKenzie Laurie J, Woodard Terri L, Johnson Helen M
Аннотация
BACKGROUND: The oncologic safety of preoperative controlled ovarian stimulation (COS) for fertility preservation in women with an in situ estrogen receptor positive (ER+) breast cancer is unclear. The purpose of this study was to compare oncologic outcomes of women with ER+ breast cancer undergoing preoperative COS versus (1) postoperative COS or (2) matched controls not undergoing COS.
PATIENTS AND METHODS: This was a single-institution retrospective cohort study of women with ER+ breast cancer receiving oncofertility counseling who pursued COS from 2014-2024. The primary outcome was progression-free survival (PFS). A subcohort of patients who received neoadjuvant systemic therapy was compared with a matched cohort of similar patients with ER+ breast cancer who did not undergo COS. Propensity score matching criteria were age, HER2 receptor status, and clinical stage.
RESULTS: Among 51 women with ER+ breast cancer undergoing COS, the median follow-up was 5.5 years. 5-year PFS was similar for preoperative COS (n = 32) versus postoperative COS (n = 19): 94.1% (95% CI 65.0-99.2%) versus 93.3% (95% CI 61.3-99.0%), p = 0.73. Patients undergoing neoadjuvant systemic therapy (NST) and preoperative COS (n = 30) experienced a significantly longer time from diagnosis to NST initiation than propensity-score matches who did not undergo COS (48 versus 29.5 days, p < 0.0001), but disease-free survival was similar: 94.1% (95% CI 65.0-99.2%) versus 93.3% (95% CI 75.9-98.3%), p = 0.15.
CONCLUSIONS: In this study of women with ER+ breast cancers, preoperative COS was not associated with increased risks of disease progression or death. While COS was associated with a modest delay in NST initiation, PFS was similar to propensity-score matched patients who did not undergo COS. Results support the oncologic safety of COS in the setting of an in situ ER+ tumor and provide much-needed evidence for young women with breast cancer receiving gonadotoxic NST who desire future childbearing during survivorship.
PATIENTS AND METHODS: This was a single-institution retrospective cohort study of women with ER+ breast cancer receiving oncofertility counseling who pursued COS from 2014-2024. The primary outcome was progression-free survival (PFS). A subcohort of patients who received neoadjuvant systemic therapy was compared with a matched cohort of similar patients with ER+ breast cancer who did not undergo COS. Propensity score matching criteria were age, HER2 receptor status, and clinical stage.
RESULTS: Among 51 women with ER+ breast cancer undergoing COS, the median follow-up was 5.5 years. 5-year PFS was similar for preoperative COS (n = 32) versus postoperative COS (n = 19): 94.1% (95% CI 65.0-99.2%) versus 93.3% (95% CI 61.3-99.0%), p = 0.73. Patients undergoing neoadjuvant systemic therapy (NST) and preoperative COS (n = 30) experienced a significantly longer time from diagnosis to NST initiation than propensity-score matches who did not undergo COS (48 versus 29.5 days, p < 0.0001), but disease-free survival was similar: 94.1% (95% CI 65.0-99.2%) versus 93.3% (95% CI 75.9-98.3%), p = 0.15.
CONCLUSIONS: In this study of women with ER+ breast cancers, preoperative COS was not associated with increased risks of disease progression or death. While COS was associated with a modest delay in NST initiation, PFS was similar to propensity-score matched patients who did not undergo COS. Results support the oncologic safety of COS in the setting of an in situ ER+ tumor and provide much-needed evidence for young women with breast cancer receiving gonadotoxic NST who desire future childbearing during survivorship.